Clinical Trials for Prostate Cancer
PHEN’s “Find Your Trial (FYT)” search tool connects patients with actively recruiting prostate cancer clinical trials that can possibly benefit them. The FYT tool has seven easy to use searchable categories to help patients find and review clinicals trials based on where they are on their prostate cancer journey. All trials listed have links to important information, including description, study locations, contacts and more.
All Trials
Find Your Trial
LEGION-100 Patient Summary – Metastatic Castration-Resistant Prostate Cancer
Background Metastatic castration-resistant prostate cancer (mCRPC) is prostate cancer that has spread to other parts of the body and continues to grow despite very low testosterone levels. While several treatments are available, new and more effective therapies are...
The Role of PARP Inhibitors in Prostate Cancer Management
What Are PARP Inhibitors? PARP inhibitors (often called PARPi) are cancer medicines you take as pills. PARP is a protein your cells use to fix small breaks in their DNA. PARP inhibitors block this repair process. When cancer cells can’t fix their DNA damage, they may...
T-Cell Engager Therapy for Prostate Cancer: An Easy-to-Understand Guide
Prostate cancer is often treatable. Many people do well with surgery, radiation, or hormone therapy. However, sometimes the cancer comes back. Sometimes it spreads to other parts of the body. When that happens, doctors and researchers look for new options. One option...
Saruparib Patient Summary – High-Risk Prostate Cancer
Saruparib is a new pill that blocks PARP1, a protein cancer cells use to repair DNA. Laboratory and early‑phase studies indicated 60 mg once a day as the recommended dose. Adding saruparib might hold the cancer in check for longer. Phase 3 Trial of Saruparib...
IDeate/Prostate02 Patient Summary – Metastatic Castration Resistant
MK-2400-01A: Substudy of I-DXd-based Treatment Combinations or as Monotherapy in mCRPC Testing I-DXd alone or in combination with other treatments for people with metastatic castration-resistant prostate cancer (mCRPC). About This Study Metastatic castration-resistant...
I-DXd Patient Summary – Metastatic Castration Resistant
Phase 3 Study of I-DXd Versus Docetaxel in mCRPC (MK-2400-001/IDeate-Prostate01) Testing I-DXd alone versus docetaxel for people with metastatic castration-resistant prostate cancer (mCRPC) About This Study Metastatic castration-resistant prostate cancer is a cancer...
ProstACT Global Patient Summary – Metastatic Castration Resistant
Phase 3 ProstACT™ Global: A Study of 177Lu-TLX591 + Standard of Care vs. Standard of Care Alone in PSMA Positive mCRPC – Clinical Trial Overview Patient Summary Purpose of This Study The Phase 3 ProstACT™ Global study is investigating whether adults treated after only...
XALute Patient Summary – Metastatic Castration Resistant
A research study for men with advanced prostate cancer. A Phase 3, open-label, multicenter, randomized study of Xaluritamig vs Cabazitaxel or second androgen receptor-directed therapy in subjects with Metastatic castration resistant prostate cancer previously treated...
ARASTEP Patient Summary – Cancer Recurrence
This trial is no longer actively recruiting.A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) in Men With Hormone Sensitive Prostate Cancer and Rise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP) Darolutamide in...
MEVPRO-1 Patient Summary – Metastatic Castration Resistant
Background Information: Prostate cancer, one of the most common types of cancer, becomes metastatic when it spreads to other parts of the body. Surgery or radiation alone cannot fully treat metastatic prostate cancer, so patients often undergo hormone therapy. ...
Find Your Trial
Low Risk
Intermediate Risk
High Risk
Cancer Recurrence
Non-Metastatic Castration Resistant
Metastatic Castration Sensitive
Metastatic Castration Resistant
This information is for educational purposes only and not intended as medical advice.
Patients should consult their medical doctor for advice and recommendations about specific clinical trials.